A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients With Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Tinostamustine (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Mundipharma Research
Most Recent Events
- 22 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jul 2024.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2023 Planned End Date changed from 30 Jul 2024 to 30 Nov 2024.